Pharmacogenomics Market to Reach USD 17.92 Billion by 2031, Growing at 9.93% CAGR

The global pharmacogenomics market is expanding at a brisk pace as personalized medicine moves from a niche concept to a mainstream clinical practice. Valued at USD 8.47 billion in 2023, the market is projected to grow from USD 9.24 billion in 2024 to USD 17.92 billion by 2031, reflecting a compound annual growth rate (CAGR) of 9.93% over the forecast period, supported by expanding regulatory backing for genomic medicine and deepening collaboration between pharmaceutical companies and research institutions.

Understanding Pharmacogenomics

Pharmacogenomics is a scientific discipline focused on understanding how an individual's genetic makeup influences their response to specific drugs. By analyzing variations in genes that affect drug metabolism, efficacy, and the likelihood of adverse effects, the field enables healthcare providers to personalize treatment plans in ways that were simply not possible with a one-size-fits-all approach to prescribing. In practice, pharmacogenomics blends genomic data with pharmacology to guide medication choice and dosing based on a patient's genetic profile, ultimately aiming to improve treatment effectiveness while minimizing the risk of adverse drug reactions.

Rising Cancer Rates Fuel Demand for Personalized Treatment

A significant driver behind the market's growth is the increasing prevalence of chronic diseases, particularly cancer, which is intensifying demand for personalized medicine approaches. The American Cancer Society estimated in January 2024 that more than 2 million new cancer cases would be diagnosed in the United States that year, an increase from the roughly 1.9 million cases reported the previous year. This growing disease burden is fueling demand for tailored treatments, as personalized therapies become increasingly essential for improving patient outcomes and managing increasingly complex treatment regimens.

Rising research funding is reinforcing this trend. The National Cancer Institute reported that cancer research funding in the United States climbed from USD 6.72 billion in 2022 to USD 7.10 billion in 2023, evidence of substantial ongoing investment in genomics and personalized medicine. Key industry players are working to capitalize on this funding growth by developing more advanced genetic testing technologies and personalized treatment options, investing in research while forging strategic partnerships with healthcare providers to accelerate innovation and drive broader market demand.

Precision Medicine Initiatives Expand the Opportunity

The market is poised for substantial additional growth as precision medicine, which integrates genetic and environmental data to customize treatments based on individual disease characteristics, continues to gain traction across healthcare systems. The National Cancer Institute's June 2023 introduction of the Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice, known as ComboMATCH, exemplifies this approach by assessing optimal drug combinations specifically tailored to the tumor biology of individual cancer patients.

Initiatives like ComboMATCH underscore a broader trend toward personalized treatment strategies, fueled by continued advancements in digital technologies and biological research. As precision medicine continues evolving, the pharmacogenomics market is expected to expand meaningfully to meet growing demand for more effective, individually tailored therapeutic solutions across a range of disease areas.

Integration Costs and Reimbursement Remain Persistent Hurdles

Even with strong tailwinds, the pharmacogenomics market faces an ongoing challenge tied to the complexity and cost of integrating genetic testing into routine clinical workflows. Varying reimbursement policies and inconsistent regulatory frameworks across different regions further complicate widespread adoption, creating real friction for healthcare providers looking to incorporate pharmacogenomic testing into standard care.

Key industry players are actively working to mitigate these challenges through heavy investment in research aimed at validating the clinical efficacy of pharmacogenomic testing, advocacy for standardized guidelines, and deeper strategic collaboration with healthcare stakeholders. These combined efforts are directed at overcoming existing barriers and promoting broader acceptance of pharmacogenomics as a core pillar of personalized medicine, ultimately supporting continued market growth alongside improved patient care outcomes.

Direct-to-Consumer Testing Reshapes the Landscape

The rise of direct-to-consumer (DTC) genetic testing companies is fundamentally reshaping how the pharmacogenomics market operates. These companies are providing cost-effective, accessible genetic testing kits that allow consumers to gain meaningful insight into their genetic predispositions and potential responses to specific drugs, all without requiring a clinical visit to initiate testing.

Growing consumer awareness and interest in personal health genomics continues to propel this segment forward, as more individuals seek to understand their own genetic makeup and how it might inform their healthcare decisions. As DTC genetic testing companies capture a growing share of the broader market, they are simultaneously fostering innovation and contributing meaningfully to the pharmacogenomics industry's overall growth trajectory.

Segment-Level Performance

By product, sequencing kits generated the highest revenue in 2023, at USD 3.01 billion, offering essential tools for pharmacogenomic testing that allow healthcare providers to analyze the genetic variations influencing individual drug responses; this segment is expected to reach USD 5.88 billion by 2031. By service type, DNA sequencing captured the largest market share at 41.52% in 2023, as advances in next-generation sequencing have significantly reduced both costs and turnaround times, making genetic testing more broadly accessible to healthcare providers and patients alike. By indication, the cancer segment is expected to generate the highest revenue by 2031, an estimated USD 6.99 billion, reflecting oncology's leading role in applying genetic testing to tailor cancer therapies based on individual tumor profiles. By application, drug discovery is projected to capture the largest share by 2031, at 35.88%, as pharmaceutical companies increasingly leverage genomic insights to identify genetic markers that influence drug response and optimize both efficacy and safety during development.

Regional Landscape: North America Leads, Asia-Pacific Set to Accelerate

North America held the largest regional share of the market in 2023, at approximately 33.81%, equivalent to a valuation of USD 2.86 billion. This leadership position reflects high investment in personalized medicine and drug discovery activities, a robust healthcare infrastructure, and a high prevalence of chronic diseases across the region. The Canadian Cancer Society reported in November 2023 that 239,100 Canadians were expected to be diagnosed with cancer that year, with around 45% of individuals in Canada facing a cancer diagnosis at some point in their lifetime, underscoring the scale of demand driving regional adoption of pharmacogenomic solutions. New service launches, such as the University of Florida College of Pharmacy's February 2023 introduction of MyRx, a virtual consultation service helping patients understand pharmacogenetic testing results, are further expected to boost regional adoption.

Asia-Pacific is anticipated to witness the fastest growth of any region, at a robust CAGR of 12.38% through 2031, reaching an estimated market value of USD 5.02 billion by that year. This growth is being fueled by expanding healthcare infrastructure, increasing government initiatives supporting genomics research, and growing awareness of personalized medicine across the region. Countries including China and India are investing heavily in healthcare modernization and genomic studies, while rising disposable incomes and improving healthcare access are together driving increased demand for advanced medical treatments, supported further by expanding collaboration between academic institutions and biotech companies.

Competitive Landscape

Leading companies in the pharmacogenomics market, including Abbott, Agilent Technologies, Becton Dickinson, Biomerieux, Bio-Rad Laboratories, Eurofins Genomics, F. Hoffmann-La Roche, Illumina, PacBio, and PerkinElmer, are pursuing strategies centered on partnerships, mergers and acquisitions, and product innovation to expand their portfolios and increase market share across regions. Companies continue investing heavily in research and development while establishing new service delivery centers and optimizing operational processes to unlock further growth opportunities. In May 2024, Oxford Nanopore Technologies introduced a new Pharmacogenomics Beta Programme designed to advance personalized medicine by combining Twist Bioscience's next-generation sequencing target enrichment technology with Oxford Nanopore's sequencing platform, an initiative expected to enhance both the accuracy and efficiency of pharmacogenomic testing going forward.

Outlook

As chronic disease prevalence continues to rise and precision medicine becomes further embedded in standard clinical practice, the pharmacogenomics market is well positioned for sustained growth through 2031. Companies that can successfully lower integration costs while continuing to validate clinical efficacy are best placed to capture the substantial opportunity this rapidly evolving field presents.